Resmed Names Salli Schwartz as Chief Investor Relations Officer
Werte in diesem Artikel
Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community
SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO.
Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins ResMed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she led the company’s investor engagement strategy, representing the company’s response to shareholders’ perspectives on corporate strategy, capital allocation, and financial performance. She was also a member of Illumina’s Corporate Social Responsibility Executive Steering Committee and its Transformation Office.
"Salli is a seasoned financial leader with a proven track record of driving investor relationships supporting business strategy and capital efficiency,” said Farrell. "Her leadership and expertise will be critical as we advance our 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential.”
Prior to Illumina, Schwartz served as Head of Investor Relations and Treasurer at MSCI, Inc., where she managed investor communications as well as a portfolio of over $2 billion in cash and short-term investments, and more than $4 billion in high-yield debt. She was also a member of MSCI’s Corporate Responsibility Committee, Enterprise Risk Oversight Committee, and Investment Committee. Earlier in her career, Schwartz held multiple roles at Moody's Corporation, including Global Head of Strategic Capital Management and Treasurer, and Global Head of Investor Relations and Communications. She also worked in corporate strategy, corporate treasury, and FP&A with Citigroup Inc.
"I am excited to join Resmed at such a pivotal moment in its strategy to make better sleep and breathing health more accessible around the world,” said Schwartz. "I look forward to partnering with our leadership team and our shareholders to communicate and advance Resmed’s vision and financial targets.”
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible, and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
For Media: | For Investors: | |
Kristen Handley Slater | Mike Ott or Wendy Wilson | |
news@resmed.com | investorrelations@resmed.com |

Ausgewählte Hebelprodukte auf Resmed
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Resmed
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu ResMed Inc.
Analysen zu ResMed Inc.
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | ResMed Outperform | BMO Capital Markets | |
23.01.2018 | ResMed Hold | Needham & Company, LLC | |
25.09.2017 | ResMed Underweight | Barclays Capital | |
04.08.2017 | ResMed Outperform | BMO Capital Markets | |
24.01.2017 | ResMed Hold | Canaccord Adams |
Datum | Rating | Analyst | |
---|---|---|---|
14.12.2018 | ResMed Outperform | BMO Capital Markets | |
04.08.2017 | ResMed Outperform | BMO Capital Markets | |
14.05.2015 | ResMed Buy | Needham & Company, LLC | |
23.01.2015 | ResMed Buy | Needham & Company, LLC | |
10.08.2009 | ResMed overweight | JP Morgan Chase & Co. |
Datum | Rating | Analyst | |
---|---|---|---|
23.01.2018 | ResMed Hold | Needham & Company, LLC | |
24.01.2017 | ResMed Hold | Canaccord Adams | |
27.06.2016 | ResMed Underperform | Needham & Company, LLC | |
17.12.2015 | ResMed Hold | Needham & Company, LLC | |
25.06.2015 | ResMed Equal Weight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
25.09.2017 | ResMed Underweight | Barclays Capital | |
07.04.2016 | ResMed Underweight | Barclays Capital | |
27.01.2015 | ResMed Under Perform | Northland Capital |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für ResMed Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen